Conatus Pharmaceuticals Inc. (CNAT)

[Inoviorulez]

That's true, but the POLT study didn't fail because emricasan didn't work. It's just that the biopsy that was done had 3 F6 fibrosis placebo patients obtain 100%. For a severe cirrhosis of the liver and to obtain 100% was a major anomaly which is just not possible. My thinking is that the biopsy was done on a part of the liver that was not affected and was fully healed. As for the ENCORE-PH I think it has a better shot because measurement is with HVPG measuring the portal hypertension vein of the liver, and not a biopsy. In addition, the POLT study only used one dose of emricasan 25 mg. The ENCORE-PH study is using 3 doses of emricasan 5 mg, 25 mg, and 50 mg twice daily vs placebo twice daily.